SWITCHING FROM DOUBLE-BLIND ENTACAPONE OR PLACEBO TO OPEN-LABEL OPICAPONE: NMSS RESULTS (1-YEAR EXTENSION BIPARK-I STUDY)

被引：0
|
作者：
Fabregues, O. [1 ]
Tolosa, E. [2 ]
Ferreira, J. [3 ]
Lees, A. [4 ]
Santos, A. [5 ]
Rocha, J. [6 ]
Soares-Da-Silva, P. [5 ]
机构：
[1] Univ Hosp Vall dHebron, Barcelona, Spain
[2] Hosp Clin Univ Barcelona, Barcelona, Spain
[3] Inst Med Mol, Neurol Clin Res Unit, Lisbon, Portugal
[4] Natl Hosp Neurol & Neurosurg, London, England
[5] BIAL Portela & Co SA, Global Parkinson Dis, Sao Mamede do Coronado, Portugal
[6] BIAL Portela & Co SA, Res & Dev, Sao Mamede do Coronado, Portugal
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2019年 / 90卷 / 12期
关键词：
D O I：
10.1136/jnnp-2019-ABN-2.133
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
141
引用
收藏
页码：E49 / E49
页数：1
相关论文
共 50 条
  • [31] Efficacy of opicapone in Parkinson's disease patients with 'early' motor fluctuations: Responder analyses from the BIPARK-I double-blind experience
    Ferreira, J.
    Lees, A.
    Poewe, W.
    Rascol, O.
    Santos, A.
    Arbe, E.
    Rocha, J-F.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2018, 33 : S103 - S104
  • [32] Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
    van der Heijde, Desiree
    Deodhar, Atul
    Maksymowych, Walter P.
    Sieper, Joachim
    Van den Bosch, Filip
    Kim, Tae-Hwan
    Kishimoto, Mitsumasa
    Ostor, Andrew J.
    Combe, Bernard
    Sui, Yunxia
    Duan, Yuanyuan
    Wung, Peter K.
    Song, In-Ho
    RMD OPEN, 2022, 8 (02):
  • [33] Efficacy responders to opicapone among Parkinson's disease patients with 'early' motor fluctuations: data from the BIPARK-I double-blind experience
    Ferreira, J.
    Lees, A.
    Poewe, W.
    Rascol, O.
    Santos, A.
    Arbe, E.
    Rocha, J.
    Soares-Da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 155 - 155
  • [34] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION
    van der Heijde, Desiree
    Deodhar, Atul
    Maksymowych, Walter P.
    Sieper, Joachim
    van den Bosch, Filip
    Kim, Tae-Hwan
    Kishimoto, Mitsumasa
    Ostor, Andrew
    Combe, Bernard
    Sui, Yunxia
    Duan, Yuanyuan
    Chu, Alvina D.
    Song, In-Ho
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 26 - 26
  • [35] Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
    van der Heijde, Desiree
    Deodhar, Atul
    Maksymowych, Walter
    Sieper, Joachim
    Van den Bosch, Filip
    Kim, Tae-Hwan
    Kishimoto, Mitsumasa
    Ostor, Andrew
    Combe, Bernard
    Sui, Yunxia
    Duan, Yuanyuan
    Chu, Alvina D.
    Song, In-Ho
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1925 - 1928
  • [36] Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2-year double-blind, placebo-controlled, randomized trial plus 1-year open-label extension
    Worm, Margitta
    Rak, Sabina
    Samolinski, Boleslaw
    Antila, Jukka
    Hoiby, Ann-Sofi
    Kruse, Brigitte
    Lipiec, Agnieszka
    Rudert, Michael
    Valovirta, Erkka
    CLINICAL AND EXPERIMENTAL ALLERGY, 2019, 49 (04): : 516 - 525
  • [37] Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study
    Mease, Philip J.
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : 402 - 411
  • [38] Efficacy of opicapone in Parkinson's disease patients with 'early' motor fluctuations: UPDRS-II and III analysis from the BIPARK-I double-blind experience
    Ebersbach, G.
    Ferreira, J.
    Stocchi, F.
    Costa, R.
    Arbe, E.
    Rocha, J-F.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2018, 33 : S148 - S148
  • [39] Efficacy of opicapone in Parkinson's disease patients with 'early' motor fluctuations: Patient and Clinical Global Impression of Change from the BIPARK-I double-blind experience
    Rocha, J.
    Stocchi, F.
    Lees, A.
    Ferreira, J.
    Poewe, W.
    Rascol, O.
    Santos, A.
    Magalhaes, D.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2019, 34 : S79 - S79
  • [40] Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
    Takashi Wada
    Masaya Inagaki
    Toru Yoshinari
    Ryuji Terata
    Naoko Totsuka
    Miki Gotou
    Gaia Hashimoto
    Clinical and Experimental Nephrology, 2021, 25 : 120 - 130
12345